Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Wit, D. de
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(13)
+
-
Availability
Open access
(1)
+
-
Metadata Only
(13)
+
-
Creation Date
2015
(6)
+
-
2013
(3)
+
-
2014
(2)
+
-
2016
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(13)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(13)
+
-
Topic
Sunitinib
(3)
+
-
pharmacokinetics
(3)
+
-
Everolimus
(2)
+
-
Pharmacokinetics
(2)
+
-
TDM
(2)
+
-
pazopanib
(2)
+
-
Show more
Author
Wit, D. de
(14)
+
-
Erp, N.P. van
(13)
+
-
Gelderblom, H.
(11)
+
-
Guchelaar, H.J.
(11)
+
-
Hartigh, J. den
(7)
+
-
Kapiteijn, E.
(4)
+
-
Hollander, M. den
(3)
+
-
Links, T.P.
(3)
+
-
Schneider, T.C.
(3)
+
-
Demetri, G.D.
(2)
+
-
Hessing, T.
(2)
+
-
Hoeven, J.J.M. van der
(2)
+
-
Huitema, A.D.R.
(2)
+
-
Khosravan, R.
(2)
+
-
Konig-Quartel, J.M.C.
(2)
+
-
Morreau, H.
(2)
+
-
Sparreboom, A.
(2)
+
-
Wezel, T. van
(2)
+
-
Wiltshire, R.
(2)
+
-
Show more
Language
en
(14)
+
-
Search results
(1 - 14 of 14)
show grid
show list
save search
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial
A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib
Dose optimization of oral targeted therapies in oncology
Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer
A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
CYP3A4 phenotyping with midazolam to predict sunitinib exposure
The influence of gastrointestinal resection on sunitinib exposure in GIST patients